September 30, 2021 | CRISPR, Impetus Digital, Jessica Schwaber, Natalie Yeadon, Solupore, allogeneic therapies, cell engineering, cell therapy, gene therapy, gene-editing, non-viral modalities, precision medicine, viral modalities
Jessica Schwaber, Scientific Director, Cell & Gene Therapy, Avectas, explores her company’s unique cell engineering platform, the recent shift in cell & gene therapy commercial needs, current barriers to realizing the full potential of cell & gene therapy, and much more.
This content was provided by Impetus Digital
Company Details
Latest Content from Impetus Digital
Stephany Lapierre, Founder and CEO of Tealbook sits down with us in this Fireside Chat. Stephany is a highly coveted supply chain thought-leader, and one of the most influential minds in…
Jon Sockell, Co-founder and COO of Limbix, sits down with us in this Fireside Chat. See how Limbix is paving the way for prescription digital therapeutics and learn from their trials,…
In this session, we discussed systems change, wicked problems, and multisolving. We reviewed the transformational changes that can evolve and go beyond “cause and effect” thinking. In this dialogue, we…
Find out how Impetus Digital helped virtualize their client’s internal brand planning session
Eddie Power, Vice President of North America Medical Affairs, Hospital Business at Pfizer, discusses a range of topics, including the effects of COVID-19 on the way Medical Affairs teams work and…
Ladana Edwards, Partner at Deloitte Central Europe and Thomas de Bruyne, Consultant with Deloitte Belgium, share their thoughts on the future of education and the role of digital technologies such as virtual…
A holistic view of how to work with patients virtually
